BR112019005144A2 - sistema regulador de expressão, composição, métodos para expressar uma proteína, para induzir/reativar a proliferação de cardiomiócitos neonatais ou adultos e para expressar um gene de interesse, vetor, kit regulador de expressão, e, uso. - Google Patents
sistema regulador de expressão, composição, métodos para expressar uma proteína, para induzir/reativar a proliferação de cardiomiócitos neonatais ou adultos e para expressar um gene de interesse, vetor, kit regulador de expressão, e, uso.Info
- Publication number
- BR112019005144A2 BR112019005144A2 BR112019005144-9A BR112019005144A BR112019005144A2 BR 112019005144 A2 BR112019005144 A2 BR 112019005144A2 BR 112019005144 A BR112019005144 A BR 112019005144A BR 112019005144 A2 BR112019005144 A2 BR 112019005144A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- interest
- expression regulatory
- expressing
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395701P | 2016-09-16 | 2016-09-16 | |
| US62/395,701 | 2016-09-16 | ||
| PCT/US2017/052035 WO2018053414A1 (en) | 2016-09-16 | 2017-09-18 | Cell-specific expression of modrna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019005144A2 true BR112019005144A2 (pt) | 2019-06-04 |
Family
ID=61619271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019005144-9A BR112019005144A2 (pt) | 2016-09-16 | 2017-09-18 | sistema regulador de expressão, composição, métodos para expressar uma proteína, para induzir/reativar a proliferação de cardiomiócitos neonatais ou adultos e para expressar um gene de interesse, vetor, kit regulador de expressão, e, uso. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11299749B2 (https=) |
| EP (2) | EP3512567B1 (https=) |
| JP (2) | JP7432362B2 (https=) |
| CN (1) | CN110177578B (https=) |
| AU (2) | AU2017326535B2 (https=) |
| BR (1) | BR112019005144A2 (https=) |
| CA (1) | CA3036710A1 (https=) |
| ES (1) | ES2967788T3 (https=) |
| WO (1) | WO2018053414A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3512567B1 (en) * | 2016-09-16 | 2023-11-01 | Icahn School of Medicine at Mount Sinai | Cell-specific expression of modrna |
| JP7440868B2 (ja) * | 2018-03-30 | 2024-02-29 | 国立大学法人京都大学 | 細胞の製造方法 |
| BR112022002365A2 (pt) | 2019-08-09 | 2022-04-26 | Nutcracker Therapeutics Inc | Métodos e aparelhos para fabricar e para remover material de uma composição terapêutica |
| WO2021092440A1 (en) | 2019-11-07 | 2021-05-14 | Icahn School Of Medicine At Mount Sinai | Synthetic modified rna and uses thereof |
| EP4058584A4 (en) * | 2019-11-11 | 2023-12-20 | Icahn School of Medicine at Mount Sinai | GENE DELIVERY SYSTEMS FOR THE TREATMENT OF HEART FAILURE |
| EP4351623A1 (en) | 2021-06-09 | 2024-04-17 | Icahn School of Medicine at Mount Sinai | Gene combination as a broad spectrum antiviral |
| EP4355882A2 (en) * | 2021-06-15 | 2024-04-24 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
| CN114085834A (zh) * | 2021-11-16 | 2022-02-25 | 珠海中科先进技术研究院有限公司 | 一种癌细胞导向电路组及应用 |
| EP4514965A1 (en) * | 2022-04-27 | 2025-03-05 | The Penn State Research Foundation | Modrna-based cas endonuclease and base editor and uses thereof |
| US20230364267A1 (en) * | 2022-05-13 | 2023-11-16 | The Uab Research Foundation | Pre-clinical modified rna approaches used in large animals for muscle and vascular regeneration |
| EP4282963A1 (en) * | 2022-05-23 | 2023-11-29 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Nucleic acid modified biological cell with expansion-dependent gene expression |
| WO2024015729A1 (en) * | 2022-07-11 | 2024-01-18 | Icahn School Of Medicine At Mount Sinai | Regulatory system for expression of a gene of interest in a target cell and method of use thereof |
| US20260035707A1 (en) * | 2022-07-26 | 2026-02-05 | Modernatx, Inc. | Engineered polynucleotides for temporal control of expression |
| CN116785501A (zh) * | 2022-08-04 | 2023-09-22 | 上海交通大学医学院附属上海儿童医学中心 | 促进心脏组织修复的modRNA转染改造的细胞及其应用 |
| WO2024151975A1 (en) | 2023-01-13 | 2024-07-18 | Igor Lednev | Detecting degradation of a polynucleotide by raman spectroscopy |
| CN119120571B (zh) * | 2024-09-11 | 2026-03-17 | 武汉科技大学 | 一种治疗hiv感染的靶向外泌体嵌合抗原受体分子的构建及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08506008A (ja) | 1992-11-18 | 1996-07-02 | アーチ ディベロプメント コーポレイション | 心筋及び血管平滑筋へのアデノウィルス介在遺伝子移入 |
| US20090005336A1 (en) * | 2007-05-08 | 2009-01-01 | Zhiguo Wang | Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions |
| KR20240136456A (ko) * | 2009-12-07 | 2024-09-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 세포 리프로그래밍을 위한 정제된 변형 ｒｎａ를 포함하는 ｒｎａ 제제 |
| US9458509B2 (en) * | 2010-07-22 | 2016-10-04 | President And Fellows Of Harvard College | Multiple input biologic classifier circuits for cells |
| EP2694660B1 (en) | 2011-04-03 | 2018-08-08 | The General Hospital Corporation | Efficient protein expression in vivo using modified rna (mod-rna) |
| EP2584040A1 (en) * | 2011-10-17 | 2013-04-24 | Pharmahungary 2000 Kft. | Compounds for treatment of ischemic injury |
| CA2915627A1 (en) * | 2012-06-15 | 2013-12-19 | The General Hospital Corporation | Inhibitors of micrornas that regulate production of atrial natriuretic peptide (anp) as therapeutics and uses thereof |
| WO2014093574A1 (en) * | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
| US10538740B2 (en) | 2014-03-20 | 2020-01-21 | Kyoto University | Method for sorting cardiomyocytes |
| WO2016040395A1 (en) * | 2014-09-08 | 2016-03-17 | Massachusetts Institute Of Technology | Rna-based logic circuits with rna binding proteins, aptamers and small molecules |
| EP3512567B1 (en) * | 2016-09-16 | 2023-11-01 | Icahn School of Medicine at Mount Sinai | Cell-specific expression of modrna |
-
2017
- 2017-09-18 EP EP17851710.8A patent/EP3512567B1/en active Active
- 2017-09-18 ES ES17851710T patent/ES2967788T3/es active Active
- 2017-09-18 AU AU2017326535A patent/AU2017326535B2/en active Active
- 2017-09-18 JP JP2019514770A patent/JP7432362B2/ja active Active
- 2017-09-18 CN CN201780070205.9A patent/CN110177578B/zh active Active
- 2017-09-18 BR BR112019005144-9A patent/BR112019005144A2/pt unknown
- 2017-09-18 WO PCT/US2017/052035 patent/WO2018053414A1/en not_active Ceased
- 2017-09-18 EP EP23205982.4A patent/EP4316587A3/en active Pending
- 2017-09-18 CA CA3036710A patent/CA3036710A1/en active Pending
-
2019
- 2019-03-15 US US16/354,814 patent/US11299749B2/en active Active
-
2022
- 2022-03-28 US US17/705,609 patent/US12215336B2/en active Active
-
2023
- 2023-06-07 JP JP2023093720A patent/JP2023123520A/ja active Pending
- 2023-11-23 AU AU2023270313A patent/AU2023270313A1/en active Pending
-
2024
- 2024-12-27 US US19/003,758 patent/US20250154523A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023123520A (ja) | 2023-09-05 |
| EP3512567B1 (en) | 2023-11-01 |
| JP2019528736A (ja) | 2019-10-17 |
| CA3036710A1 (en) | 2018-03-22 |
| CN110177578B (zh) | 2024-02-13 |
| US12215336B2 (en) | 2025-02-04 |
| US20190203226A1 (en) | 2019-07-04 |
| EP3512567A4 (en) | 2020-03-18 |
| US20220220501A1 (en) | 2022-07-14 |
| AU2017326535B2 (en) | 2023-08-24 |
| EP4316587A3 (en) | 2024-04-24 |
| CN110177578A (zh) | 2019-08-27 |
| AU2017326535A1 (en) | 2019-04-18 |
| US11299749B2 (en) | 2022-04-12 |
| US20250154523A1 (en) | 2025-05-15 |
| WO2018053414A1 (en) | 2018-03-22 |
| ES2967788T3 (es) | 2024-05-03 |
| EP4316587A2 (en) | 2024-02-07 |
| EP3512567A1 (en) | 2019-07-24 |
| JP7432362B2 (ja) | 2024-02-16 |
| EP3512567C0 (en) | 2023-11-01 |
| AU2023270313A1 (en) | 2024-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019005144A2 (pt) | sistema regulador de expressão, composição, métodos para expressar uma proteína, para induzir/reativar a proliferação de cardiomiócitos neonatais ou adultos e para expressar um gene de interesse, vetor, kit regulador de expressão, e, uso. | |
| BR112019006384A2 (pt) | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas | |
| BR112018073606A2 (pt) | polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos | |
| BR112018074325A2 (pt) | anticorpo para ligação a receptor de interleucina 4 | |
| BR112018016443A2 (pt) | sistema de transposon replicativo | |
| BR112022002695A2 (pt) | Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso | |
| BR112018076394A2 (pt) | genes de minidistrofina otimizados e cassetes de expressão e seu uso | |
| BR112019007309A2 (pt) | anticorpos anti-c1s e métodos de uso dos mesmos | |
| BR112018010639A2 (pt) | método de transfecção transitória para produção retroviral. | |
| BR112021012665A2 (pt) | Polipeptídeos úteis para edição de genes e métodos de uso | |
| BR112019006388A2 (pt) | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| BR112019011277A2 (pt) | polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos. | |
| BR112017014917A2 (pt) | elementos regulatórios pós-transcricionais modificados de hepatite | |
| BR112018075399A2 (pt) | sistema de distribuição viral não integrativo e métodos relacionados a este | |
| BR112019011582A2 (pt) | anticorpos e métodos de utilização dos mesmos | |
| BR112019012964A2 (pt) | polipeptídeos multiméricos moduladores de célula t e métodos de uso dos mesmos | |
| BR112021025130A2 (pt) | Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos | |
| CL2020000937A1 (es) | Anticuerpo multiespecífico. | |
| AR095596A1 (es) | Moléculas de unión de cadena única comprendiendo n-terminal abp | |
| BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
| BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| BR112019000015A2 (pt) | distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15V | Prolongation of time limit allowed |
Free format text: TENDO EM VISTA A PORTARIA INPI NO 334 DE 24/09/2020, QUANTO AOS PRAZOS VENCIDOS ENTRE 16/09/2020 A 25/09/2020, DEVOLVE-SE O PRAZO NESSE PEDIDO COM RELACAO A SOLICITACAO DO PEDIDO DE EXAME. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |